BB Biotech AG's Form 4 filing
Black Diamond Therapeutics, Inc.BDTX · filed Mar 20, 2025
- Accession no.
- 0001104659-25-026305
- Filed
- Mar 20, 2025, 9:01 PM ET
- Trade date
- Mar 19, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions. Open-market sales total $12.0M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BB Biotech AGCIK 0000924223 | 10% Owner |
| Biotech Growth N VCIK 0001259869 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 19, 2025 | Common Stock | SSaleDisposed | −1,000,000 | $2.07 | −$2,069,100 | 7,517,839 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −300,000 | $1.94 | −$582,900 | 7,217,839 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −1,000,000 | $2.31 | −$2,308,100 | 6,217,839 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −2,000,000 | $2.00 | −$4,000,800 | 4,217,839 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −400,000 | $2.09 | −$837,160 | 3,817,839 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −584,292 | $1.95 | −$1,141,239.13 | 3,233,547 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −500,000 | $2.12 | −$1,058,450 | 2,733,547 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Biotech Growth N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Black Diamond Therapeutics, Inc. held directly or indirectly by Biotech Growth N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Growth N.V.